Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy
type: MedicalStudy
description: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy
status: TERMINATED
study design: INTERVENTIONAL
phase: PHASE3
start date: 2019-11-13
end date: 2021-03-18
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://clinicaltrials.gov/study/NCT04115839
source organization: US National Library of Medicine
publisher: AI Analytics
sponsor: Gilead Sciences
study subject: Psoriatic Arthritis
keywords: PHASE3
keywords: INTERVENTIONAL
keywords: TERMINATED
keywords: Psoriatic Arthritis

AI Analytics
type: Organization